Verastem, Inc. (VSTM)
NASDAQ: VSTM · Real-Time Price · USD
5.87
+0.06 (1.03%)
At close: Aug 5, 2026, 4:00 PM EDT
5.87
0.00 (0.06%)
After-hours: Aug 5, 2026, 7:49 PM EDT
Verastem Employees
Verastem had 102 employees as of December 31, 2025. The number of employees increased by 24 or 30.77% compared to the previous year.
Employees
102
Change (1Y)
24
Growth (1Y)
30.77%
Revenue / Employee
$486,127
Profits / Employee
-$1,901,559
Market Cap
515.82M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 102 | 24 | 30.77% |
| Dec 31, 2024 | 78 | 5 | 6.85% |
| Dec 31, 2023 | 73 | 16 | 28.07% |
| Dec 31, 2022 | 57 | 9 | 18.75% |
| Dec 31, 2021 | 48 | 0 | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Autolus Therapeutics | 754 |
| Valneva SE | 674 |
| Arvinas | 246 |
| Prime Medicine | 146 |
| Adlai Nortye | 109 |
| Artiva Biotherapeutics | 106 |
| Cybin | 100 |
| Silence Therapeutics | 88 |
VSTM News
- 8 days ago - Verastem doses first patients in Target-D 203 Phase 2 trial - TheFly
- 8 days ago - Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer - Business Wire
- 13 days ago - Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026 - Business Wire
- 14 days ago - Verastem doses first patient in TARGET-D 202 Phase 2 trial - TheFly
- 14 days ago - Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer - Business Wire
- 4 weeks ago - Verastem price target lowered to $14 from $15 at RBC Capital - TheFly
- 4 weeks ago - Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 6 weeks ago - Verastem Transcript: Study update - Transcripts